A Randomized Open Label Study Evaluating the Efficacy of Continuous Telbivudine Versus Lamivudine in Patients With HBeAg-negative Chronic Hepatitis B Who Had Previously Achieved an Undetectable Viral Load During 24 Weeks of Telbivudine Therapy.
Phase of Trial: Phase IV
Latest Information Update: 20 Jun 2013
At a glance
- Drugs Lamivudine (Primary) ; Telbivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms SASL28
- 20 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Nov 2009 New trial record